ICAM1 and ocular toxoplasmosis: Another group recently reported that a small molecule integrin antagonist, lifitegrast, decreased ocular expression of ICAM-1, CD11a, and CD18 at the protein level and diminished the pathological disruption of the retinal architecture when administered topically to eyes of mice with experimental ocular toxoplasmosis [214].